Forbion related stories
All articles and analysis
Side Letter: PE's entry barrier; Pictet's double close; Niche index updateMonday is a bank holiday in the UK due to King Charles's coronation this weekend, so Side Letter will return on Tuesday. For now, institutional investors face a knowledge gap when pondering an entry into private markets. Plus: nice news for niche investors. Here’s today's brief, for our valued subscribers only.
Side Letter: Thoma Bravo's timing; PE's job creation credentials; Korea's VC supportThoma Bravo's apparent eagerness to hit the fundraising trail could prove advantageous at a time when the process is slower-going. Plus: Invest Europe shines a light on PE's job creation credentials; and Korea's government wants to back domestic VCs. Here’s today's brief, for our valued subscribers only.
CHART: The biggest dedicated life sciences capital raisersDedicated life sciences firms with strong AUM growth have been prime targets for larger GPs recently – here's a list of firms ranked by capital raised.
US steps up as European LPs 'strike’ over BrexitUK private equity funds are under increased scrutiny from continental investors but US LPs seem to have fewer doubts.
Forbion increases bite size after first close – exclusiveThe Dutch VC firm held a first close on €270m for Fund IV this week just two months after launch, managing partner Sander Slootweg told PEI.
Forbion in $450m pharma dealThe sale comes as Forbion is currently attempting to collect €150m for Fund III
- Dutch first-timer reaches halfway mark on €150m fund
Netherlands-based Holland Private Equity has held a €77m interim close on its way to a target of €150m. The firm has also inked its first investment.
- Forbion strengthens investor base
Secondaries specialist Coller Capital, the principal backer of Forbion Capital Partners’ spin-out from ABN AMRO Capital, has moved to diversify the firm’s investor base by selling part of its stake to seven leading private equity investor groups.
- Forbion strengthens investor base(2)
Secondaries specialist Coller Capital, the principal backer of Forbion Capital Partners’ spin-out from ABN AMRO Capital, has moved to diversify the firm’s investor base by selling part of its stake to seven leading private equity investor groups.
- ABN AMRO spins out life sciences group
ABN AMRO Capital has spun out its life sciences venture arm, which operates a €200m life sciences fund, focused on the US and Europe.